Compare CENT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENT | RARE |
|---|---|---|
| Founded | 1955 | 2010 |
| Country | United States | United States |
| Employees | 6000 | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | N/A | 2013 |
| Metric | CENT | RARE |
|---|---|---|
| Price | $35.61 | $24.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 20 |
| Target Price | $50.00 | ★ $59.10 |
| AVG Volume (30 Days) | 43.6K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | $1.60 | $13.12 |
| Revenue Next Year | $2.04 | $37.80 |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $28.77 | $18.29 |
| 52 Week High | $41.25 | $40.17 |
| Indicator | CENT | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 59.90 |
| Support Level | $35.12 | $23.69 |
| Resistance Level | $36.70 | $25.70 |
| Average True Range (ATR) | 1.02 | 0.99 |
| MACD | -0.25 | -0.02 |
| Stochastic Oscillator | 5.83 | 47.62 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.